Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, while coverage for Leqembi, another Alzheimer's treatment approved this year, is still under review, a health official overseeing the NHI system said yesterday.
Kisunla has already been reviewed by an expert panel, which concluded that although the drug has completed Phase 3 clinical trials, the follow-up period for users was too short and its long-term benefits remain unclear, National Health Insurance Administration Director-General Shih Chung-liang (石崇良) said in a legislative session.
Given the drug's high cost and references to health technology agencies in the UK, Australia and Canada — none of which recommended it for coverage by public health insurance — the panel decided against recommending it for inclusion in the NHI system, Shih said.
Photo: CNA file photo
As for Leqembi, Shih said its application for NHI coverage was submitted last month and is currently under review.
The drug is to undergo a 45-day Health Technology Assessment (HTA) before being reviewed by an expert panel, with a decision expected early next year, he added.
Jointly developed by Eisai in Japan, Biogen in the US and BioArctic in Sweden, Leqmebi was approved by the US Food and Drug Administration in July 2023, while Kisunla, developed by US pharmaceutical company Eli Lilly, received a green light in July last year.
The two medications received approval from Food and Drug Administration earlier this year, but have not been covered by the NHI system, requiring patients to pay out of pocket for treatments that cost more than NT$1 million (US$33,398) per year.
An estimated 350,000 people in Taiwan have some form of dementia, 60 to 70 percent of whom have Alzheimer's disease, said Yan Sui-hing (甄瑞興), director of Far Eastern Memorial Hospital's dementia center.
Yan said about half of those with Alzheimer's may be eligible for the two new treatments, which target patients in the early stages of the disease, totaling fewer than 100,000 people.
Unlike previous medications, Kisunla and Leqembi are the first new treatments for Alzheimer's disease that target the underlying cause rather than just its symptoms, according to hospital, which administered the first dose of Kisunla in Taiwan on June 23.
In terms of expected outcomes, the complete elimination of amyloid plaques — which many researchers believe to be a key cause of Alzheimer's disease due to their abnormal accumulation in the brain — was seen in nearly 70 percent of patients within a year of receiving the two drugs, according to New Taipei Municipal Tucheng Hospital, one of the first hospitals in Taiwan to offer Leqembi.
Leqembi has the potential to slow the progression of Alzheimer's disease by 27 percent to 51 percent, while patients receiving Kisunla may see a 29 to 36 percent reduction in disease progression, the Tucheng Hospital added.
A magnitude 6.1 earthquake struck off the coast of Yilan County at 8:39pm tonight, the Central Weather Administration (CWA) said, with no immediate reports of damage or injuries. The epicenter was 38.7km east-northeast of Yilan County Hall at a focal depth of 98.3km, the CWA’s Seismological Center said. The quake’s maximum intensity, which gauges the actual physical effect of a seismic event, was a level 4 on Taiwan’s 7-tier intensity scale, the center said. That intensity level was recorded in Yilan County’s Nanao Township (南澳), Hsinchu County’s Guansi Township (關西), Nantou County’s Hehuanshan (合歡山) and Hualien County’s Yanliao (鹽寮). An intensity of 3 was
Instead of focusing solely on the threat of a full-scale military invasion, the US and its allies must prepare for a potential Chinese “quarantine” of Taiwan enforced through customs inspections, Stanford University Hoover fellow Eyck Freymann said in a Foreign Affairs article published on Wednesday. China could use various “gray zone” tactics in “reconfiguring the regional and ultimately the global economic order without a war,” said Freymann, who is also a nonresident research fellow at the US Naval War College. China might seize control of Taiwan’s links to the outside world by requiring all flights and ships entering or leaving Taiwan
The next minimum wage hike is expected to exceed NT$30,000, President William Lai (賴清德) said yesterday during an award ceremony honoring “model workers,” including migrant workers, at the Presidential Office ahead of Workers’ Day today. Lai said he wished to thank the awardees on behalf of the nation and extend his most sincere respect for their hard work, on which Taiwan’s prosperity has been built. Lai specifically thanked 10 migrant workers selected for the award, saying that although they left their home countries to further their own goals, their efforts have benefited Taiwan as well. The nation’s industrial sector and small businesses lay
Taiwan's first indigenous defense submarine, the SS-711 Hai Kun (海鯤, or Narwhal), departed for its 13th sea trial at 7am today, marking its seventh submerged test, with delivery to the navy scheduled for July. The outing also marked its first sea deployment since President William Lai (賴清德) boarded the submarine for an inspection on March 19, drawing a crowd of military enthusiasts who gathered to show support. The submarine this morning departed port accompanied by CSBC Corp’s Endeavor Manta (奮進魔鬼魚號) uncrewed surface vessel and a navy M109 assault boat. Amid public interest in key milestones such as torpedo-launching operations and overnight submerged trials,
RSS